United Therapeutics
UTHR · What the business does, what can go wrong, and how options sellers approach it
What it does
United Therapeutics is a biotechnology company focused on rare cardiopulmonary diseases, most notably pulmonary arterial hypertension (PAH). PAH is a progressive condition in which blood pressure in the arteries of the lungs is abnormally high.
Its best-known medicines are built around treprostinil and come in several forms: an inhaled powder (Tyvaso DPI), an infused or injected version (Remodulin), and an oral tablet (Orenitram). It also sells Adcirca and Unituxin. Beyond drugs, the company has long-term research in areas such as organ manufacturing and transplantation.
How it makes money
Most revenue comes from selling prescription medicines, mainly in the United States. The Tyvaso inhaled treprostinil franchise has been a major contributor. Because these are specialty drugs for a small patient population, each patient represents meaningful recurring revenue. Generic and competing versions of some products can affect sales over time.
Why investors own it
Investors are typically drawn to its established PAH franchise, its history of strong profitability for a biotech company, and its pipeline, including efforts to expand treprostinil into related lung diseases. Some also watch whether the company returns cash through share buybacks.
What can go wrong
- Concentration: a single product family drives much of the business.
- Competition from new PAH treatments and generic treprostinil.
- Clinical trial setbacks or regulatory delays in pipeline programs.
- Drug pricing pressure from insurers and government programs.
- Long-dated projects, such as organ manufacturing, may take years to pay off, if they do at all.
What to watch
- Tyvaso franchise prescription trends
- Clinical trial results and regulatory decisions for new indications
- Patent and generic competition developments
- Remodulin and Orenitram sales trends
- Drug pricing and reimbursement policy changes
- Share repurchase activity
Options income angle
Options on UTHR are generally available across many expirations, but liquidity is typically thinner than for the most heavily traded stocks, so bid-ask spreads can be wider, especially on far-from-the-money strikes. Implied volatility tends to rise ahead of earnings, clinical trial readouts, and regulatory decisions. A key caution for anyone selling premium: a surprise trial or regulatory result can cause a sharp price gap that overwhelms the premium collected, so covered calls can cap upside and cash-secured puts can leave you owning shares after a large drop.
Follow UTHR in Kortex
The Kortex app shows UTHR's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.